Skip to content

Blood Transfusions in Thalassemia Patients, Complications and Adverse Effects

Blood Transfusions in Thalassemia Patients, Complications and Adverse Effects.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00971880
Enrollment
100
Registered
2009-09-04
Start date
2009-05-31
Completion date
2010-11-30
Last updated
2011-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sickle Cell Anemia, Thalassemia

Keywords

Blood transfusions, Adverse events, Hepatitis C, HIV

Brief summary

Patients suffering from Thalassemia or another hemoglobinopathies required regular blood transfusions. The complications and adverse effects of blood transfusions can be classified as immediate and late. Among the immediate effects the most common are allergic reactions and fever, besides congestive heart failure in patients with cardiomyopathy. The late effects are mostly related to blood transmitted infections like HIV or Hepatitis C infections. The purpose of this study is to summarize the data of those complications in a cohort of 100 patients receiving regular blood transfusion.

Detailed description

About 100 patients aged several months to 50 years are treated in the Pediatric Hematology Unit, most of those patients receive blood transfusions monthly. The adverse reactions were routinely recorded during each transfusion. All the patients were also screened annually for the incidence of blood transmitted infections principally HIV and Hepatitis C. All those records will be systematically screened and all the immediate or late adverse reactions and complications related to blood transfusions will be summarized. A second goal of this study will be to control the staff strictness related to the ministry of health protocol dealing to blood transfusions.

Interventions

OTHERClinical medical record summary

Summary of immediate and late adverse effects of blood transfusions

Sponsors

HaEmek Medical Center, Israel
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Months to 50 Years
Healthy volunteers
No

Inclusion criteria

* Patients receiving blood transfusions due to chronic hematologic disorders

Exclusion criteria

* Not applicable

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026